RxDoctor Payments Data

Marylou Stanton

Family · Sidney, NYNPI 1487035739

Payments from drug & device makers

$360in general payments, 2019–2025

Across 17 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$123
  • AstraZeneca$41
  • Indivior Inc.$36
  • Novo Nordisk$35
  • GSK$33
  • Pfizer$32
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$360100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$360 in reported general payments places this provider in the 50th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$43,407
Medicare patients
153
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$114,058
EliquisApixaban78$94,909
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$81,028
TrulicityDulaglutide55$75,437
FarxigaDapagliflozin Propanediol36$47,991
JanuviaSitagliptin Phosphate28$42,551
RybelsusSemaglutide14$24,062
JanumetSitagliptin Phos/Metformin Hcl18$15,226
XareltoRivaroxaban20$14,830
Tresiba Flextouch U-200Insulin Degludec16$14,208
Combivent RespimatIpratropium/Albuterol Sulfate24$13,227
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,802
JardianceEmpagliflozin13$10,320
Incruse ElliptaUmeclidinium Bromide20$7,939
Albuterol Sulfate HfaAlbuterol Sulfate174$7,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$35$138,12184 claims
GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta, Breo Ellipta$33$99,729120 claims
PfizerEliquis$32$94,90978 claims
Lilly USA, LLCTrulicity$18$75,43755 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$41$66,23069 claims
AbbVieSynthroid$123$2,11748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,883 family providers in New York.

Other family in Sidney

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →